CircASH2 enhances the LLPS of nuclear Y-box binding protein 1 (YBX1) in hepatocellular carcinoma, and also enhances the attenuation of the primary target protein tropomyosin 4 (TPM4) transcripts, thereby altering the tumor cytoskeleton structure to inhibit HCC metastasis [27]. Here, YBX1 is linked to hepatocellular carcinoma.